Nautilus Biotechnology Inc (NASDAQ:NAUT) — Stock Price
Nautilus Biotechnology Inc (NASDAQ:NAUT) is currently trading at $0.87 USD, down 3.89% today. Over the past 52 weeks, shares have ranged between $0.64 and $3.95. This page tracks Nautilus Biotechnology Inc's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see NAUT company net worth.
Nautilus Biotechnology Inc (NAUT) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Nautilus Biotechnology Inc's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Nautilus Biotechnology Inc Income Statement — Revenue, Profit & Earnings by Year
Nautilus Biotechnology Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $6.35 Million | $5.71 Million | $3.42 Million | $2.84 Million | $2.35 Million |
| Gross Profit | $-6.35 Million | $-5.71 Million | $-3.42 Million | $-2.84 Million | $-2.35 Million |
| Research & Development | $50.48 Million | $47.25 Million | $36.45 Million | $26.51 Million | $10.09 Million |
| SG&A | $31.00 Million | $28.90 Million | $25.95 Million | $21.15 Million | $3.31 Million |
| Total Operating Expenses | $75.12 Million | $70.45 Million | $60.20 Million | $47.66 Million | $13.40 Million |
| Operating Income | $-81.48 Million | $-76.15 Million | $-63.62 Million | $-50.50 Million | $-15.74 Million |
| EBITDA | $-64.43 Million | $-74.30 Million | $-54.51 Million | $-47.47 Million | $-13.27 Million |
| EBIT | $-70.78 Million | $-76.15 Million | $-57.92 Million | $-50.31 Million | $-15.62 Million |
| Interest Expense | — | — | $5.82 Million | $183.00K | $0.00 |
| Income Before Tax | $-70.78 Million | $-63.67 Million | $-57.92 Million | $-50.31 Million | $-15.62 Million |
| Income Tax Expense | $-70.78 Million | — | $5.82 Million | $2.61 Million | $2.14 Million |
| Net Income | $-70.78 Million | $-63.67 Million | $-57.92 Million | $-50.31 Million | $-15.62 Million |
Nautilus Biotechnology Inc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Nautilus Biotechnology Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $242.74 Million | $305.56 Million | $350.05 Million | $398.45 Million | $85.01 Million |
| Total Current Assets | $132.83 Million | $176.84 Million | $187.21 Million | $349.22 Million | $77.66 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $102.25 Million | $154.02 Million | $69.95 Million | $160.11 Million | $40.13 Million |
| Net Receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | $3.70 Million | $2.48 Million | $6.21 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $34.01 Million | $40.21 Million | $35.13 Million | $34.87 Million | $114.73 Million |
| Total Current Liabilities | $7.63 Million | $9.12 Million | $6.79 Million | $5.81 Million | $3.02 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $2.83 Million | $15.23 Million | $-84.19 Million | $-155.59 Million | $-31.83 Million |
| Total Stockholder Equity | $208.73 Million | $265.35 Million | $314.92 Million | $363.58 Million | $-29.72 Million |
| Retained Earnings | $-273.02 Million | $-202.24 Million | $-138.56 Million | $-80.64 Million | $-30.32 Million |
Nautilus Biotechnology Inc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Nautilus Biotechnology Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-59.15 Million | $-51.71 Million | $-45.81 Million | $-39.24 Million | $-14.00 Million |
| Capital Expenditures | $2.12 Million | $2.44 Million | $2.32 Million | $2.27 Million | $921.00K |
| Free Cash Flow | $-61.27 Million | $-54.15 Million | $-48.13 Million | $-41.51 Million | $-14.92 Million |
| Investing Cash Flow | $66.25 Million | $-43.73 Million | $-25.74 Million | $-138.96 Million | $-25.28 Million |
| Financing Cash Flow | $1.14 Million | $368.00K | $562.00K | $327.45 Million | $75.90 Million |
| Dividends Paid | — | — | — | — | $52.95K |
| Stock-Based Compensation | $12.70 Million | $12.14 Million | $10.38 Million | $7.93 Million | $369.00K |
| Depreciation | $6.35 Million | $5.71 Million | $3.42 Million | $2.84 Million | $2.35 Million |
| Change in Cash | $8.25 Million | $-95.08 Million | $-70.98 Million | $149.24 Million | $36.62 Million |
Nautilus Biotechnology Inc Earnings History — EPS Actual vs. Analyst Estimates
Track Nautilus Biotechnology Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 05, 2026 | 0.00 | -0.17 | +100.00% |
| Feb 19, 2026 | 0.00 | -0.16 | +100.00% |
| Oct 28, 2025 | -0.11 | -0.15 | +26.67% |
| Jul 31, 2025 | -0.12 | -0.15 | +20.00% |
| Apr 29, 2025 | -0.13 | -0.15 | +13.33% |
| Feb 27, 2025 | -0.14 | -0.15 | +6.67% |
| Oct 29, 2024 | -0.13 | -0.17 | +23.53% |
| Jul 30, 2024 | -0.14 | -0.16 | +12.50% |